Vumedi Cardiology

What defines optimal PCI strategy in three-vessel disease today? In this Vumedi presentation from TCT 2025, Dr. Patrick Serruys reviews the evolving data and clinical reasoning shaping revascularization decisions in complex multivessel coronary disease. 3 Key Takeaways: -Heart team collaboration remains essential for choosing between PCI and CABG in complex anatomy. -Physiology and imaging (FFR, IVUS, OCT) guide completeness of revascularization and improve outcomes. -Modern drug-eluting stents and technique refinement continue to close the gap between PCI and surgery for selected patients. 💬 “Three-vessel disease isn’t one disease—it’s a spectrum. Precision in patient selection is the new best practice.” — Dr. Patrick Serruys 🎥 Watch the full TCT 2025 discussion now on Vumedi - https://lnkd.in/gpSVqCZg #PCI #TCT2025 #InterventionalCardiology #CoronaryDisease #FFR #VumediCardio

Amyloid heart disease is increasingly recognized—and highly treatable when diagnosed early. In this #Vumedi presentation, Dr. Mahwash Kassi (Houston Methodist Hospital) outlines a systematic, imaging-centered approach to diagnosing cardiac amyloidosis. 3 Key Takeaways: -Early suspicion is critical: Look for HFpEF with LV thickening, low-voltage ECG, or carpal tunnel syndrome. -Rule out AL first: Light chain assays are essential before imaging to avoid false positives. -Imaging guides diagnosis: PYP scintigraphy confirms ATTR; CMR defines burden; PET holds promise for subtype differentiation. 💬 “Amyloid isn’t as rare as we once thought—it’s just underdiagnosed.” — Dr. Mahwash Kassi 🎥 Watch the full lecture on #Vumedi - https://lnkd.in/ggQPxrTP #Cardiology #Amyloidosis #HFpEF #Imaging #CMR #NuclearCardiology #VumediCardio

How safe and effective is catheter-directed therapy for PE? At TCT 2025, Dr. Wissam Jaber (Emory University Hospital) presented the interim analysis of the RAPID-PE study, evaluating real-world outcomes in catheter-directed thrombolysis for intermediate-risk pulmonary embolism. 3 Key Takeaways: -Rapid RV recovery: Significant improvements in RV/LV ratio and oxygenation within 24 hours. -Safety signal: Low major bleeding rates with tailored, lower-dose thrombolytic strategies. -Clinical relevance: Supports early intervention in selected intermediate-risk PE patients. 💬 “The RAPID-PE data highlight a balance between efficacy and safety that could redefine PE treatment pathways.” — Dr. Jaber - https://lnkd.in/gZzTAXqf 🎥 Watch the full TCT 2025 analysis now on Vumedi. #PulmonaryEmbolism #InterventionalCardiology #TCT2025 #Thrombolysis #VumediCardio

Hypertension control is evolving—with new data, new tools, and a new mindset. In this #Vumedi presentation, Dr. Prashanth D. Thakker from Washington University School of Medicine in St. Louis reviews the latest hypertension guidelines and the emerging role of renal denervation for resistant cases. 3 Key Takeaways: -Updated guidelines redefine thresholds—130/80 mmHg marks stage 1 hypertension. -Resistant hypertension affects up to 20% of patients; multidisciplinary management is key. -Renal denervation offers a new interventional option for patients uncontrolled on multiple agents. 💬 “We can’t just give up at 145 systolic—every mmHg matters.” — Dr. Thakker 🎥 Watch the full discussion on #Vumedi - https://lnkd.in/gFVrjrvB #Hypertension #RenalDenervation #Guidelines #VumediCardio

Thank you Dr. Ninios for sharing your insights with Vumedi!

Imaging is redefining hypertrophic cardiomyopathy care. In this #Vumedi presentation, Dr. Milind Desai MD MBA (Cleveland Clinic) discusses how advanced imaging—echo, CMR, CT, and AI tools—is transforming the diagnosis, risk assessment, and treatment of HCM. 3 Key Takeaways: -Multimodality imaging matters: Echo is the gatekeeper, while CMR and CT provide complementary structural and tissue insights. -AI and stress testing enhance detection and phenotyping, identifying hidden gradients and non-obstructive HCM variants. -Imaging drives therapy: Key in guiding myosin inhibitor use, surgical referral, and longitudinal follow-up. 💬 “Different imaging modalities are not interchangeable—consistency and context matter.” — Dr. Milind Desai 🎥 Watch the full lecture on #Vumedi - https://lnkd.in/guMSaF3R #VumediCardio #HCM #Imaging #Echocardiography #CMR #AI 

Is vulnerable plaque a valid therapeutic target—or a diagnostic distraction? In this #Vumedi presentation, Dr. Carlos Collet (Aalst Cardiovascular Center, Belgium) discusses how advances in CT, IVUS, OCT, and computational physiology are redefining how we detect and treat plaques before they rupture. 3 Key Takeaways: -Beyond stenosis: Composition, inflammation, and plaque stress—not just narrowing—determine rupture risk. -Physiology meets imaging: Pressure gradients (ΔFFR) and plaque burden together refine vulnerability prediction. -Next frontier: AI and advanced CT may guide who benefits from preventive PCI versus intensified medical therapy. 💬 “Plaque rupture occurs when the force of blood exceeds the resistance of the plaque—understanding that balance is the future of prevention.” — Dr. Collet 🎥 Watch the full FACET session on #Vumedi - https://lnkd.in/gePZnqke #VumediCardio #Atherosclerosis #CoronaryImaging #InterventionalCardiology #PrecisionMedicine 

The 2025 ASE Diastolic Function Guidelines are here. In this #Vumedi presentation, Dr. @Sherif Nagueh (Houston Methodist) provides an in-depth review of the updated American Society of Echocardiography (ASE) recommendations for evaluating diastolic function. 3 Key Takeaways: -Age-specific cutoffs are now incorporated for tissue Doppler velocities (E′) to improve diagnostic precision. -Revised algorithms for estimating left atrial pressure enhance accuracy and reduce indeterminate classifications. -New pathways for assessing diastolic function in HFpEF, AFib, and pulmonary hypertension improve clinical applicability. 💬 “These updates make diastolic assessment more physiologic—and more practical for daily echo practice.” — Dr. Nagueh 🎥 Watch the full ASE 2025 guideline overview on #Vumedi - https://lnkd.in/gfSCVgjq #VumediCardio #Echocardiography #ASE #HFpEF #Imaging #ClinicalGuidelines 

Is it time to redefine refractory angina? In this #Vumedi session from MonteHeart Lectures, Dr. Ranil De Silva outlines a precision-based approach to managing patients with angina that persists despite optimal therapy or revascularization. 3 Key Takeaways: -Refractory angina is evolving: Beyond epicardial disease, mechanisms include coronary microvascular dysfunction and vasospasm. -Precision diagnostics: Combining noninvasive imaging (MRI, PET) and invasive physiology allows stratified, mechanism-driven therapy. -Integrated care models: Multidisciplinary “angina heart teams” improve outcomes through coordinated evaluation and symptom management. 💬 “Refractory angina isn’t untreatable—it’s under-diagnosed.” — Dr. De Silva 🎥 Watch the full discussion now on #Vumedi - https://lnkd.in/gMuz86fs #VumediCardio #RefractoryAngina #PrecisionMedicine #InterventionalCardiology #MicrovascularAngina

How is digital health transforming cardiovascular prevention? In this #Vumedi discussion hosted by the American Society for Preventive Cardiology (ASPC), Drs. Ami Bhatt, Mintu Turakhia, Seth Martin, and Keerthana Pakanati explore how AI, wearables, and patient engagement are redefining preventive cardiology. Key Insights: -From monitoring to management: Remote data must drive clinical action, not just measurement. -Patient agency matters: Empowering patients—not just clinicians—is key to scalable prevention. -Bridging the digital divide: Thoughtful design can expand, not restrict, access to care. 💬 “We can’t close the prevention gap without giving patients real agency.” — Dr. Ami Bhatt 🎥 Watch the full conversation on #Vumedi - https://lnkd.in/gth-8aJB #VumediCardio #DigitalHealth #Prevention #AI #Innovation #ASPC